The downgrade from Buy to Neutral by Citigroup, a major financial institution, indicates a less optimistic outlook for Rain Oncology's stock. Additionally, the significant reduction in the price target from $24 to $1.5 suggests that the analyst believes the stock is overvalued, which could lead to a short-term decline in the stock price.